Biogen Inc. $BIIB Shares Bought by B. Metzler seel. Sohn & Co. AG

Key Points

• B. Metzler seel. Sohn & Co. AG increased its Biogen stake by 140.1% in Q4, buying 17,489 shares to hold 29,971 shares valued at $5.275 million, while several other large institutions also materially boosted positions and institutional investors collectively own 87.93% of the stock.
• Analysts have lifted price targets—Oppenheimer at $275 and UBS upgrading to a Buy with a $225 target—but ratings are mixed and the MarketBeat consensus remains a Hold with a $211.31 target price.
• Biogen beat quarterly estimates with EPS of $1.99 versus $1.61 and revenue of $2.28 billion, and set FY2026 guidance of $15.25–$16.25 earnings per share.

B. Metzler seel. Sohn & Co. AG raised its position in Biogen Inc. (NASDAQ:BIIB - Free Report) by 140.1% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 29,971 shares of the biotechnology company's stock after purchasing an additional 17,489 shares during the period. B. Metzler seel. Sohn & Co. AG's holdings in Biogen were worth $5,275,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the company. Orion Porfolio Solutions LLC boosted its stake in shares of Biogen by 6,828.4% during the second quarter. Orion Porfolio Solutions LLC now owns 517,275 shares of the biotechnology company's stock valued at $64,965,000 after acquiring an additional 509,809 shares during the last quarter. Caisse de depot et placement du Quebec boosted its stake in shares of Biogen by 718.2% during the third quarter. Caisse de depot et placement du Quebec now owns 569,253 shares of the biotechnology company's stock valued at $79,741,000 after acquiring an additional 499,676 shares during the last quarter. AQR Capital Management LLC boosted its stake in shares of Biogen by 30.7% during the third quarter. AQR Capital Management LLC now owns 1,783,581 shares of the biotechnology company's stock valued at $248,809,000 after acquiring an additional 418,776 shares during the last quarter. Alyeska Investment Group L.P. boosted its stake in shares of Biogen by 66.1% during the third quarter. Alyeska Investment Group L.P. now owns 845,277 shares of the biotechnology company's stock valued at $118,406,000 after acquiring an additional 336,504 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of Biogen by 425.3% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 348,404 shares of the biotechnology company's stock valued at $48,804,000 after acquiring an additional 282,084 shares during the last quarter. Institutional investors and hedge funds own 87.93% of the company's stock.

More Biogen News

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: UBS upgraded BIIB to Buy and raised its price target to $225, citing a “slew of pipeline catalysts” over the next 12–15 months that could materially boost revenue and valuation. Biogen upgraded by UBS on ‘slew of pipeline catalysts’ going into 2027
• Neutral Sentiment: Several analysts issued mixed takes — some raising targets but keeping neutral ratings, which suggests upside is acknowledged but not consensus conviction. This readjusts expectations without flipping broad buy/sell positioning. Analysts’ Opinions Are Mixed on These Healthcare Stocks: Biogen (BIIB)...
• Neutral Sentiment: JPMorgan raised its price target to $185 but kept a Neutral rating — marginally higher valuation support but still limited upside per their view. MarketScreener: JPMorgan adjusts price target on Biogen to $185
• Neutral Sentiment: Rothschild & Co Redburn raised its target to $180 but kept a Neutral rating — another example of price‑target lift without a buy endorsement. MarketScreener: Rothschild & Co Redburn adjusts Biogen price target to $180
• Neutral Sentiment: Jim Cramer noted he’s “reopening the file” on Biogen after recent coverage and upgrades — a media boost that can support short‑term interest but isn’t an analyst endorsement. Jim Cramer Says “I Got to Reopen the File on Biogen”
• Negative Sentiment: Wolfe Research trimmed its Q1 2026 EPS estimate (from $2.79 to $2.64) even as it nudged FY‑2027 estimates higher — the near‑term cut can pressure the stock ahead of earnings.
• Negative Sentiment: HSBC reiterated a Reduce rating and uses a $150 target — a markedly lower anchor than UBS and others, which can prompt selling by investors who follow conservative sell‑side views. What is HSBC's Estimate for Biogen Q1 Earnings?
• Neutral Sentiment: Barclays reaffirmed its Hold rating — another stabilizing but non‑bullish stance. Barclays Reaffirms Their Hold Rating on Biogen (BIIB)

Analysts Set New Price Targets

A number of analysts recently commented on BIIB shares. BMO Capital Markets increased their price objective on Biogen from $165.00 to $196.00 and gave the company a "market perform" rating in a research note on Friday, February 6th. Oppenheimer increased their price objective on Biogen from $250.00 to $275.00 and gave the company an "outperform" rating in a research note on Wednesday, April 1st. JPMorgan Chase & Co. increased their price objective on Biogen from $175.00 to $185.00 and gave the company a "neutral" rating in a research note on Thursday. Wells Fargo & Company increased their price objective on Biogen from $190.00 to $200.00 and gave the company an "equal weight" rating in a research note on Sunday, February 8th. Finally, The Goldman Sachs Group reaffirmed a "buy" rating on shares of Biogen in a research note on Monday, February 9th. Fourteen research analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Hold" and a consensus target price of $211.31.

Biogen Stock Performance

NASDAQ BIIB opened at $187.88 on Friday. The business's 50-day moving average price is $185.37 and its 200 day moving average price is $174.82. Biogen Inc. has a twelve month low of $115.25 and a twelve month high of $202.41. The company has a market capitalization of $27.57 billion, a PE ratio of 21.33, a price-to-earnings-growth ratio of 2.54 and a beta of 0.16. The company has a current ratio of 2.68, a quick ratio of 2.03 and a debt-to-equity ratio of 0.34.

Biogen (NASDAQ:BIIB - Get Free Report) last released its earnings results on Friday, February 6th. The biotechnology company reported $1.99 earnings per share for the quarter, topping the consensus estimate of $1.61 by $0.38. Biogen had a return on equity of 12.64% and a net margin of 13.07%.The firm had revenue of $2.28 billion for the quarter, compared to the consensus estimate of $2.21 billion. During the same period in the prior year, the business posted $3.44 earnings per share. The firm's revenue for the quarter was down 7.2% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. On average, research analysts predict that Biogen Inc. will post 15.75 earnings per share for the current year.

Insiders Place Their Bets

In related news, insider Priya Singhal sold 2,660 shares of the stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $199.83, for a total transaction of $531,547.80. Following the transaction, the insider directly owned 8,043 shares in the company, valued at approximately $1,607,232.69. This represents a 24.85% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Company insiders own 0.18% of the company's stock.

Biogen Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer's disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company's marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.